This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Concordia Healthcare Corp.
Drug Names(s): Trerief, Excegran, zonisamide, AD-810N, E2090
Description: Zonegran blocks voltage-sensitive sodium andcalcium channels.
Dainippon and Eisai
In March 2004, Eisai purchased North American and European rights for Zonegran from Elan, who had originally licensed it from Dainippon. In March 2005, Eisai also acquired the rights from Dainippon for China, Taiwan and 14 other Asian countries.
Eisai and Concordia
In September 2014, Eisai announced that it has entered into an agreement to divest its U.S. and Puerto Rican rights for the antiepileptic agent Zonegran (zonisamide) to Concordia.
Zonegran is an antiepileptic drug (AED) originally created by Sumitomo Dainippon, for which Eisai and its U.S. subsidiary hold exclusive rights in Europe, North America and Asia. Under this agreement, Eisai will sell its commercialization rights associated with Zonegran in the U.S. and Puerto Rico to Concordia. In addition, the companies have agreed to enter into a supply agreement under which Eisai will serve as Concordias supplier of Zonegran for the U.S. and Puerto Rican market. The...See full deal structure in Biomedtracker
Partners: Sumitomo Dainippon Pharma Co., Ltd. Eisai Co., Ltd.
Pink Sheet Zonegran FDA Reviewers
Pink Sheet Zonegran Clinical Protocols
Pink Sheet Zonegran Clinical Development
Additional information available to subscribers only: